Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
Sustained Glucose Control Does Not Slow Decline of C-Peptide in Randomized T1D Study
This randomized, multicenter study of children and adolescents with new-onset type 1 diabetes (T1D) investigated the effect on glucose control of a closed-loop system, using C-peptide levels to gauge response
Improved CPMs Needed for Guiding Methotrexate Use in RA
The study analyzed 20 clinical prediction models (CPMs) for rheumatoid arthritis (RA), all of which were deemed to have a high risk of bias, leading the researchers to urge against their use to guide decision-making without addressing their limitations.
Systemic Review, Survey of Physicians Provide Insight on Targeted Therapy Use in SSc-ILD
Data from a literature review of 41 studies were analyzed and subsequently leveraged to create a survey among physicians on the use of 4 targeted therapies in systemic sclerosis-interstitial lung disease (SSc-ILD).
Researchers Outline Treatment Options for Nail Psoriasis, Other Common Nail Disorders
Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.
Low-Dose Secukinumab Shows Best PASI 90 in Pediatric Plaque Psoriasis
This analysis of 5 studies found that, compared with placebo, all biologic regimens improved Psoriasis Area and Severity Index (PASI) 90 response—considered a gold standard goal due to its correlation with quality of life.
Success in Eosinophil-Targeted Treatments for EoE Remains Limited
The researchers compiled data from studies of lirentelimab, mepolizumab, reslizumab, and benralizumab, highlighting the difficulties in finding an effective approach with eosinophil-targeted treatments for eosinophilic esophagitis (EoE).
DIY Automated Insulin Delivery Systems Bring Unique Challenges to HCPs
Do-it-yourself (DIY) automated insulin delivery systems have gained rapid uptake, yielding self-reported improvements in glycemic control and quality of life for patients, but creating unique challenges for health care providers (HCPs).
CAR T-Cell Therapy Outcomes Likely Not Influenced by Race/Ethnicity, Obesity
Researchers studied data from 5 phase 1 studies that took place between 2012 and 2021, comprising 139 infusions among patients with B-cell acute lymphoblastic leukemia who received chimeric antigen receptor (CAR) T-cell treatment.
Real-world Data Confirm Early Efficacy of Anti-IL-17A Inhibitors for Psoriasis
Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.
TNF Inhibitors Linked to Higher Risk of Psoriasis in Patients With IBD, RA
While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).
Parents of Youth With T1D Generally Prefer Virtual Visit for CGM Initiation
The interview-based study collected feedback from 16 parents of 15 youth recently diagnosed with type 1 diabetes, finding that the majority preferred a virtual continuous glucose monitoring (CGM) information initiation visit rather than an in-person visit.
Three CAR T-Cell Trials, 2 Outcomes, for Second-line LBCL Therapy
Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.
Phase 3 Study: Zanubrutinib Improves PFS Over Chemoimmunotherapy in Untreated CLL, SLL
The findings, coming from the phase 3 SEQUOIA study, found that the next-generation, selective Bruton tyrosine kinase inhibitor had superior efficacy versus chemoimmunotherapy and demonstrated an acceptable safety profile among 600 older patients with comorbidities.